VN1R1 and prostate adenocarcinoma: Among them, VN1R1 has been shown to be overexpressed in prostate adenocarcinomas and glioblastoma cancer cells [56,57] and POTED in prostate cancer patients, making it a potential molecule for targeted therapy [58].